{"schema_version":"secwatch.filing_event.v1","accession":"0001736730-26-000033","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-05-14T13:01:44+00:00","discovered_at":"2026-05-14T13:03:00.278880+00:00","generated_at":"2026-05-14T13:04:44.340883+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CAMP4 Therapeutics reports preclinical data showing CMP-002 improves seizure threshold in SYNGAP1 model","bullets":["CMP-002 produced statistically significant improvement in seizure threshold and severity in SYNGAP1 haploinsufficient mice.","Data presented at TIDES conference on May 14, 2026; builds on prior motor/behavioral benefit evidence.","Company plans to advance CMP-002 into a Phase 1/2 clinical trial in SYNGAP1-related disorder in H2 2026.","Lead candidate CMP-002 is an antisense oligonucleotide targeting regulatory RNA to upregulate SYNGAP1 protein.","Study used PTZ-induced seizure model; CMP-002 conferred resistance to tonic-clonic seizures and reduced severity."],"urls":{"canonical":"https://secwatch.observer/filing/0001736730-26-000033","json":"https://secwatch.observer/filing/0001736730-26-000033.json","markdown":"https://secwatch.observer/filing/0001736730-26-000033.md","text":"https://secwatch.observer/filing/0001736730-26-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000173673026000033/0001736730-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000173673026000033/camp-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-14T13:04:44.340883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}